Cargando…

Periorbital edema secondary to imatinib mesylate

Imatinib mesylate (Gleevec(®)) is a well-established pharmacologic treatment for all phases of chronic myeloid leukemia and for advanced gastrointestinal stromal tumors (GISTs). Edema-related side effects are relatively common in imatinib therapy with the periocular skin representing one of the most...

Descripción completa

Detalles Bibliográficos
Autores principales:	McClelland, Collin M, Harocopos, George J, Custer, Philip L
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874269/ https://www.ncbi.nlm.nih.gov/pubmed/20505834

Ejemplares similares

Complete remission of a periorbital dermatofibrosarcoma protuberans with adjuvant imatinib mesylate in a child
por: Yen, Hsi, et al.
Publicado: (2015)

Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate
por: Napolitano, Mariasanta, et al.
Publicado: (2017)

Periorbital Edema Secondary to Positive Airway Pressure Therapy
por: Dandekar, Francesco, et al.
Publicado: (2015)

Lichenoid drug eruption due to imatinib mesylate
por: Bhatia, Anuradha, et al.
Publicado: (2015)

Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007)

Generalized Lichenoid Drug Eruption Associated with Imatinib Mesylate Therapy
por: Ghosh, Sudip Kumar
Publicado: (2013)

Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)
por: Cho, Ah Young, et al.
Publicado: (2011)

Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1
por: Yasuda, Ken‐ichi, et al.
Publicado: (2020)

Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy
por: D’Addona, Matteo, et al.
Publicado: (2022)

Periorbital edema as initial manifestation of chronic cutaneous lupus erythematosus
por: Erras, Samar, et al.
Publicado: (2012)

Immediate reaction to lidocaine with periorbital edema during upper blepharoplasty
por: Presman, Benjamin, et al.
Publicado: (2016)

Massive periorbital edema following hematopoietic stem cell transplantation
por: Stallworth, Jeannette Y., et al.
Publicado: (2022)

Periorbital Edema as the Initial Manifestation of Pediatric Systemic Lupus Erythematosus
por: Kasem Ali Sliman, Rim, et al.
Publicado: (2022)

Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid Leukemia
por: Malkan, Umit Y., et al.
Publicado: (2018)

Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease
por: Platoff, Rebecca M., et al.
Publicado: (2017)

Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
por: Go, Seong Woo, et al.
Publicado: (2013)

Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)

The teratogenic effects of imatinib mesylate on rat fetuses
por: El Gendy, M.M., et al.
Publicado: (2015)

Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity
por: Musolino, Caterina, et al.
Publicado: (2015)

A Newborn with Teratogenic Effect of Imatinib Mesylate: A Very Rare Case Report
por: Jain, Namita, et al.
Publicado: (2015)

Recurrent Periorbital Cellulitis Secondary to Cyclic Neutropenia
por: Raad, Nasim, et al.
Publicado: (2020)

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)

Imatinib mesylate resistance and mutations: An Indian experience
por: Srivastava, Shweta, et al.
Publicado: (2013)

Exacerbation of Psoriasis after Imatinib Mesylate Treatment
por: Shim, Joon Ho, et al.
Publicado: (2016)

Multiple Eruptive Dermatofibromas Secondary to Imatinib Mesylate in a Patient with Chronic Myeloid Leukemia
por: Lira-Valero, Francisco J, et al.
Publicado: (2021)

Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report
por: Hughes, Brett, et al.
Publicado: (2004)

Efficacy of Imatinib Mesylate Neoadjuvant Treatment for a Locally Advanced Rectal Gastrointestinal Stromal Tumor
por: Yoon, Kyu Jong, et al.
Publicado: (2011)

Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report
por: Maiti, Baidehi, et al.
Publicado: (2009)

Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report
por: Fenocchio, Elisabetta, et al.
Publicado: (2016)

Phase II trial of imatinib mesylate in patients with metastatic melanoma
por: Kim, K B, et al.
Publicado: (2008)

Monocular hemianopia secondary to stroke
por: Samuel K Lee, et al.
Publicado: (2020)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
por: Karolewicz, Bożena, et al.
Publicado: (2019)

A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate
por: Kim, Min Sik, et al.
Publicado: (2010)

The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction
por: Staiger, Wilko I, et al.
Publicado: (2008)

Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
por: Kim, Hawk, et al.
Publicado: (2005)

Imatinib mesylate treatment for platelet-derived growth factor receptor alfa-positive choroid plexus carcinoma
por: Kawakami, Chihiro, et al.
Publicado: (2012)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate
por: Kim, Hyung Ok, et al.
Publicado: (2013)

Ageing is a risk factor in imatinib mesylate cardiotoxicity
por: Maharsy, Wael, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hlp7okvc4uhmp8lc0o9vjh3gnn